Boris V. Afanasiev – författare
Visar alla böcker från författaren Boris V. Afanasiev. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
Modern Trends in Human Leukemia IX
New Results in Clinical and Biological Research Including Pediatric Oncology
Häftad, Engelska, 1992
1 094 kr
Skickas inom 10-15 vardagar
The most recent trends in human leukemia, which were discussed at the Ninth Wilsede Meeting, are presented in this volume. The internationally renowned contributors discuss both clinical aspects as well as biomedical studies. They present new information about the biological basis of leukemia which has been gained using the methods of molecular genetics, cell and molecular biology, virology and immunology. The evidence clearly shows both the complexity of leukemia research, as well as the value of basic scientific research in furthering clinical medicine and therapy.
1 094 kr
Skickas inom 10-15 vardagar
The 11 th meeting in "Modern Trends in Human Leukemia" took place from June 19 to 21, 1994 in Wilsede in the middle of the Liineburger Heide, South of Hamburg. Interwoven with the Leukemia program was the Nato-sponsored Symposium of the ASI-Series "Gene Technology in Analysis of Malignant and Inherited Human Diseases Related to Development" . The Wilsede meeting was continued on a ship of the Neva leading through lake Ladoga and lake Onega. The topics of both meetings included discussion on recent progress isolation and development of hematopoietic stem cells, genes crucial for development and diseases, methods of gene transfer, application of gene transfer; oncogenes and anti-oncogenes as targets for gene therapy; receptors and their ligands in normal development and diseases, immunology and immunotherapy, radiation biology, clinical leukemias and bone marrow transplantation. The Nato workshop concentrated not only on analysis of cell systems useful for somatic gene therapy, but also on actual themes directly related to correction of human diseases. The latter aspects emphasized themes related to biotechnology, the first part was by nature more general. We also included a few contributions that discussed perspectives for the future of gene therapy and possible relationships to evolution.